Zobrazeno 1 - 4
of 4
pro vyhledávání: '"13/105"'
Autor:
Wrobel, Lidia, Hill, Sandra M, Djajadikerta, Alvin, Fernandez-Estevez, Marian, Karabiyik, Cansu, Ashkenazi, Avraham, Barratt, Victoria J, Stamatakou, Eleanna, Gunnarsson, Anders, Rasmusson, Timothy, Miele, Eric W, Beaton, Nigel, Bruderer, Roland, Feng, Yuehan, Reiter, Lukas, Castaldi, M Paola, Jarvis, Rebecca, Tan, Keith, Bürli, Roland W, Rubinsztein, David C
Funder: UK Dementia Research Institute
Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias.
Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ceba57a4d2ef6d23e7fdb43332a183d
Autor:
Sheng-Yu Ku, Theresa E. Hickey, Mark Daniel, Andries M. Bergman, Scott M. Dehm, Wilbert Zwart, Martin E. Gleave, Yuzhen Liu, Paari Murugan, Jason S. Carroll, Rendong Yang, Tesa M. Severson, Amina Zoubeidi, Samuel P. Pitzen, Colleen L. Forster, Manish Kohli, R. Stephanie Huang, Aashi Chaturvedi, Luke A. Selth, Loredana Puca, Andrea Sboner, Meixia Che, Josh Mentzer, Andrew C. Hsieh, Wayne D. Tilley, Ting-You Wang, Himisha Beltran, Winston Tan, Rohan Bareja, Alexander Ling, Sarah A. Munro, Jacob Hildebrand, Yanyun Zhu, Weijie Zhang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Nature Communications
Nature Communications
Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription factor. In most cases, AR activity resumes during therapy and drives progression to castration-resistant prostate cancer (CRPC). However, therapy can also promot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41e810461d5a1464f0552fc356120259
https://doi.org/10.1038/s41467-021-26612-1
https://doi.org/10.1038/s41467-021-26612-1
Autor:
Anne E. Willis, Ana Teodósio, Katarina Gyuraszova, Xiao-Ming Sun, Claire Smith, Ryan Mordue, Marco Sereno, Leah Officer, Claire Rooney, David Sumpton, Pooyeh Farahmand, Angela Rubio Tenor, Owen J. Sansom, Aristeidis P. Sfakianos, Johan Vande Voorde, Maria Guerra Martin, Gavin D. Garland, Madhumita Das, Ruth V. Spriggs, Tanya Chernova, Catherine Ficken, Alberto Marini, Marion MacFarlane, Daniel J. Murphy, Stefano Grosso, Nobu Morone, Martin Bushell, John Le Quesne
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications
Nature Communications
Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no ‘druggable’ driver oncogenes associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4634317d1a5eaacf6a942213133b30e4
https://eprints.gla.ac.uk/248582/1/248582.pdf
https://eprints.gla.ac.uk/248582/1/248582.pdf
Autor:
Georgopoulou, Dimitra, Callari, Maurizio, Rueda, Oscar M., Shea, Abigail, Martin, Alistair, Giovannetti, Agnese, Qosaj, Fatime, Dariush, Ali, Chin, Suet-Feung, Carnevalli, Larissa S., Provenzano, Elena, Greenwood, Wendy, Lerda, Giulia, Esmaeilishirazifard, Elham, O’Reilly, Martin, Serra, Violeta, Bressan, Dario, Mills, Gordon B., Ali, H. Raza, Cosulich, Sabina S., Hannon, Gregory J., Bruna, Alejandra, Caldas, Carlos, Ali, H. R., Al Sa’d, M., Alon, S., Aparicio, S., Battistoni, G., Balasubramanian, S., Becker, R., Bodenmiller, B., Boyden, E. S., Bressan, D., Bruna, A., Burger, Marcel, Caldas, C., Callari, M., Cannell, I. G., Casbolt, H., Chornay, N., Cui, Y., Dariush, A., Dinh, K., Emenari, A., Eyal-Lubling, Y., Fan, J., Fatemi, A., Fisher, E., González-Solares, E. A., González-Fernández, C., Goodwin, D., Greenwood, W., Grimaldi, F., Hannon, G. J., Harris, O., Harris, S., Jauset, C., Joyce, J. A., Karagiannis, E. D., Kovačević, T., Kuett, L., Kunes, R., Küpcü, Yoldaş A., Lai, D., Laks, E., Lee, H., Lee, M., Lerda, G., Li, Y., McPherson, A., Millar, N., Mulvey, C. M., Nugent, F., O’Flanagan, C. H., Paez-Ribes, M., Pearsall, I., Qosaj, F., Roth, A. J., Rueda, O. M., Ruiz, T., Sawicka, K., Sepúlveda, L. A., Shah, S. P., Shea, A., Sinha, A., Smith, A., Tavaré, S., Tietscher, S., Vázquez-García, I., Vogl, S. L., Walton, N. A., Wassie, A. T., Watson, S. S., Weselak, J., Wild, S. A., Williams, E., Windhager, J., Whitmarsh, T., Xia, C., Zheng, P., Zhuang, X.
Funder: Cancer Research UK (CRUK); doi: https://doi.org/10.13039/501100000289
Funder: AstraZeneca; doi: https://doi.org/10.13039/100004325
The heterogeneity of breast cancer plays a major role in drug response and resistance and has been ex
Funder: AstraZeneca; doi: https://doi.org/10.13039/100004325
The heterogeneity of breast cancer plays a major role in drug response and resistance and has been ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f430d7cb89f2265521776cbb40a97a45